Peptide LibrarySurvodutide dosage in published studies and labels
These are the doses used for Survodutide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Survodutide has no approved dosage. Human dosing comes from Boehringer Ingelheim's registered programme, where 0.6, 2.4, 3.6 and 4.8 mg once weekly were compared in a 46-week phase 2 obesity trial, and doses up to 6.0 mg once weekly were studied in metabolic liver disease and carried into phase 3. Weight loss increased across the dose range, and every dose was reached by protocol-driven escalation under trial monitoring.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.6–6.0 mg once weekly in trials |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | 46 weeks in the phase 2 obesity trial |
| Titration | Stepwise escalation to the assigned dose inside the trial protocol. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Phase 2 dose-finding trial in obesity (2024)Clinical trial · Phase 2 randomised double-blind placebo-controlled dose-finding trial | Adults aged 18–75 with BMI ≥27 and without diabetes (n=386 treated) | 0.6 mg (n=77), 2.4 mg (n=78), 3.6 mg (n=77) or 4.8 mg (n=77) | Subcutaneous | Once weekly | 46 weeks | Percentage change in body weight — −6.2% at 0.6 mg rising to −14.9% at 4.8 mg | Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024. |
| Phase 2 trial in MASH and fibrosis (2024)Clinical trial · Phase 2 randomised placebo-controlled trial | Adults with metabolic dysfunction-associated steatohepatitis and fibrosis | 2.4 mg, 4.8 mg or 6.0 mg | Subcutaneous | Once weekly | Per trial protocol | Improvement in MASH without worsening of fibrosis | A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024. |
| Phase 3 obesity trial (2026)Clinical trial · Phase 3 double-blind randomised trial | Adults with BMI ≥30, or ≥27 with an obesity-related condition | Up to 6.0 mg | Subcutaneous | Once weekly | Per trial protocol | Body weight | Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026. |
| NCT06077864 — phase 3 cardiovascular outcomesClinical trial · Phase 3 outcomes trial, completed, no results posted | Adults with obesity (n=5531) | Per trial protocol | Subcutaneous | Once weekly | — | Cardiovascular outcomes | NCT06077864 — A Study to Test the Effect of Survodutide on Cardiovascular Outcomes |
Where sources disagree
- Survodutide is not approved by any regulator. Every dose above is trial dosing, reached by protocol-driven escalation with monitoring, not a maintenance regimen.
- It is a glucagon and GLP-1 receptor dual agonist, so its dose numbers are not comparable to semaglutide or tirzepatide despite the similar milligram range and weekly interval. Glucagon receptor agonism contributes a distinct effect and side-effect profile.
- Discontinuation in the phase 2 trial was substantial — only about 60% of participants completed 46 weeks — which is part of the dose-response picture and is usually omitted when the weight-loss percentages are quoted.